

28 May 2021

DanCann Pharma A/S publishes Q1-2021 report

COPENHAGEN, Denmark, 28 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby today releases its results for the period 1 January – 31 March 2021 (the "period"). The Q1-2021 report is available as an attached document to this press release and on www.dancann.com.

KEY FIGURES Q1 2021

	01.01.21 31.03.21	01.01.20 31.03.20	01.01.20 31.12.20	01.01.19 31.12.19
KDKK				
Net sales	0	0	0	0
Operating profit (EBIT)	-2.591	-262	-5.870	-627
Result per share (DKK)*	-0,09	-341.008	-0,48	-500.000
Equity ratio	0,90	-0,72	0,89	-0,42

Number of shares 31/12/20: 20,730,800

Number of shares 31/12/19: 1

*Comparative figures are affected by the major changes in the number of shares during 2020.

CEO, Jeppe Krog Rasmussen, comments:

“Another quarter in rapid development, both in terms of business and organizational development. As a headline, of course, among other things, the new law that has made the Pilot Programme permanent for manufacturers, as well as the agreement with Tetra Bio-Pharma, which both was officially communicated and closed after the period.

First of all, I am incredibly proud of this one with Tetra Bio-Pharma, and I am very much looking forward to working with Dr. Guy Chamberland (CEO) and the Tetra team. It is with great pride, that I am able to communicate that we will be responsible for the exclusive distribution in Germany of several of Tetra Bio-Pharma products and upcoming in their pipeline.

Secondly, to put a few words on the new law for the Pilot Programme in Denmark; Perhaps the biggest risk associated with our business and our basis of existence is now eliminated? A great victory for us as a company and for our investors. A big, big day in terms of this, and quite a historical day, I would say.”

Highlights during the period:

DanCann Pharma’s strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO® technology, MON, JAN 18, 2021

DanCann Pharma A/S announced that its strategic partner, Cannassure Therapeutics Ltd. (TASE: CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products, has signed an exclusive licensing agreement with Lipidor AB (Nasdaq First North: LIPI). Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO® in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain, and lesions. DanCann Pharma is the exclusive multinational distributor of the Israelian-based company’s product portfolio for whole of Scandinavia and Finland.

DanCann Pharma A/S announced the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. for the exclusive distribution of Reduvo™ Adversa® and Qixleef™ in Scandinavia and Germany, THU, FEB 25, 2021

DanCann Pharma A/S announced the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany.

DanCann Pharma A/S: CEO Jeppe Krog Rasmussen buys shares in DanCann Pharma A/S, FRI, FEB 26, 2021

COPENHAGEN, Denmark, 26 February 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby announce that Jeppe Krog Rasmussen, Founder, Board Member and CEO at DanCann Pharma A/S has privately through his holding company (JKR INVESTMENT GROUP ApS) bought 60,000 shares in DanCann Pharma A/S at an average price of DKK 3.22 per share.

DanCann Pharma A/S: CEO Jeppe Krog Rasmussen buys more shares in DanCann Pharma A/S, WED, MAR 03, 2021

COPENHAGEN, Denmark, 3 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announce that Jeppe Krog Rasmussen, Founder, Board Member and CEO at DanCann Pharma A/S has privately through his holding company (JKR INVESTMENT GROUP ApS) bought 40,000 shares in DanCann Pharma A/S at an average price of DKK 3.14 per share.

DanCann Pharma A/S appoints Malene Gottfredsen as Product Manager, FRI, MAR 05, 2021

COPENHAGEN, Denmark, 5 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Malene Gottfredsen. Malene Gottfredsen (MSc in Pharmacy, Faculty of Pharmaceutical Sciences, University of Copenhagen) has been appointed as Product Manager at DanCann Pharma A/S.

DanCann Pharma A/S appoints Jens Markussen as Head of Production, TUE, MAR 09, 2021

COPENHAGEN, Denmark, 9 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Jens Markussen. Jens Markussen has been appointed as Head of Production at DanCann Pharma A/S.

DanCann Pharma A/S appoints Henrik Højlund Christensen as Corporate Communications Manager, MON, MAR 15, 2021

COPENHAGEN, Denmark, 15 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Henrik Højlund Christensen. Henrik Højlund Christensen has been appointed Corporate Communications Manager at DanCann Pharma A/S.

Change in the Board of Directors at DanCann Pharma A/S, FRI, MAR 19, 2021

COPENHAGEN, Denmark, 19 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announce that Magnus Østergaard Dahlmann has chosen to transfer the position of Chairman of the Board of Directors of the biopharmaceutical company DanCann Pharma A/S to Carsten Trads due to health reasons. Magnus Østergaard Dahlmann will continue as a member of the company's Board of Directors.

DanCann Pharma A/S: CEO Jeppe Krog Rasmussen upgrades his shareholding in DanCann Pharma A/S, and now holds more than 26% of the Company, MON, MAR 22, 2021

COPENHAGEN, Denmark, 22 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announce that Jeppe Krog Rasmussen, Founder, Board Member and CEO at DanCann Pharma A/S has privately through his holding company (JKR INVESTMENT GROUP ApS) bought 50,000 shares in DanCann Pharma A/S at an average price of DKK 3.25 per share.

John Morell Frellsen appointed CCO of DanCann Pharma A/S as from April 1, 2021 to accelerate the Company's European penetration, WED, MAR 31, 2021

COPENHAGEN, Denmark, 31 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") a biopharmaceutical company powered by cannabinoids today announced that John M. Frellsen has been officially appointed as Chief Commercial Officer. John M. Frellsen has been acting as interim Chief Commercial Officer for the last six months and will continue as permanent Chief Commercial Officer at DanCann Pharma. John M. Frellsen's employment with DanCann Pharma will commence in the beginning of April.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com